Skip to main content
Senti Biosciences, Inc. logo

Senti Biosciences, Inc. — Investor Relations & Filings

Ticker · SNTI ISIN · US81726A1007 US Professional, scientific and technical activities
Open in API
Filings indexed 318 across all filing types
Latest filing 2022-02-15 M&A Activity
Country US United States of America
Listing US SNTI

About Senti Biosciences, Inc.

https://www.sentibio.com/

Senti Biosciences, Inc. is a clinical-stage biotechnology company developing a new generation of cell and gene therapies. The company's core technology is its synthetic biology platform, which designs and optimizes proprietary "Gene Circuits." These circuits, created from novel combinations of DNA sequences, are engineered to reprogram cells with biological logic, enabling them to sense inputs, compute decisions, and respond to their cellular environments. This approach aims to create smarter medicines with enhanced therapeutic effectiveness and safety. Senti Bio is applying its Gene Circuit technology to develop a pipeline of product candidates, primarily for the treatment of cancer, designed to precisely target and eliminate malignant cells while sparing healthy tissue.

Recent filings

Filing Released Lang Actions
FORM 8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Dynamics Special Purpose Corp. It details amendments to a Business Combination Agreement and related support agreements, which are part of a merger transaction. The document includes legal and transactional disclosures about the merger, amendments to agreements, and forward-looking statements. It references filings such as Form S-4 and proxy statements related to the merger. The content is focused on merger-related agreements and disclosures rather than financial results, earnings, or management commentary. Therefore, this filing is best classified under M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2022-02-15 English
425 Filing
Regulatory Filings
2022-02-15 English
SC 13G/A
Major Shareholding Notification
2022-02-14 English
FORM S-4
Merger & Acquisition Classification · 95% confidence The document is a Form S-4 Registration Statement filed with the SEC, which includes a preliminary proxy statement and prospectus related to a Business Combination (merger) between Dynamics Special Purpose Corp. and Senti Biosciences, Inc. It contains detailed information about the merger agreement, share conversion ratios, and the special meeting of stockholders to approve the transaction. The document is not a financial report, earnings release, or a simple announcement but a comprehensive filing related to a merger transaction. Therefore, it fits the category of Merger & Acquisition filings (MA). The document length (15,000 characters) and content confirm it is the actual filing, not just an announcement or proxy solicitation alone.
2022-02-14 English
SC 13G/A
Major Shareholding Notification
2022-02-11 English
DYNAMICS SPECIAL PURPOSE CORP.
Major Shareholding Notification
2022-02-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.